It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
It is very uncertain whether L‐ornithine L aspartate changes serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).